Furthermore, clinical studies have demonstrated that postmenopausal women who are subjected to systemic aromatase inhibitor treatment for advanced breast cancer tend to suffer from a variety of memory defects (Bender et al., 2007; Phillips et al., 2011; Underwood et al., 2018), including impaired hippocampal-dependent memory and decreased hippocampal activity during encoding (Bayer et al., 2015), although there are dissenting studies (Hurria et al., 2014; Le Rhun et al., 2015). Here, CYP19A1 is linked to breast carcinoma.